Your browser doesn't support javascript.
loading
Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder.
Xu, Jin-Jie; Xiao, Chunfeng; Pan, Yanli; Tang, Yi-Lang; Wang, Mingwan; Li, Sheng; Xie, Gaoming; Du, Jing; Ren, Yanping; Wang, Wei.
Afiliación
  • Xu JJ; Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Xiao C; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Pan Y; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Tang YL; Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Wang M; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Li S; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Xie G; Mental Health Service Line, Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, Georgia, USA.
  • Du J; Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Ren Y; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Wang W; Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Bipolar Disord ; 26(1): 95-97, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38097824
ABSTRACT
We report the case of a Chinese male with schizoaffective disorder, an active smoker and a nonresponder to clozapine (600 mg daily). Therapeutic clozapine monitoring was analyzed, revealing a low concentration-dose ratio. A pharmacogenetic test showed that the patient had the CYP1A2*1F/*1F genotype, indicating an ultra-rapid clozapine metabolizer. In combination with fluvoxamine, a CYP1A2 enzyme inhibitor, clozapine plasma concentrations approached the reference range and achieved clinical improvement. This case demonstrates how pharmacogenetics can help understand the value of therapeutic drug monitoring to enhance the treatment of refractory schizoaffective disorder.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Antipsicóticos / Trastorno Bipolar / Clozapina Límite: Humans / Male Idioma: En Revista: Bipolar Disord Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Antipsicóticos / Trastorno Bipolar / Clozapina Límite: Humans / Male Idioma: En Revista: Bipolar Disord Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Dinamarca